OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial

Armstrong, MJ; Gaunt, Piers; Aithal, GP; Parker, Richard; Barton, Darren; Hall, D. H.; Guo, Kathy; Abouda, George; Aldersley, Mark; Gough, S; Tomlinson, J W; Brown, Rachel M.; Hübscher, S.G.; Newsome, PN

doi:10.1136/gutjnl-2015-309861.16

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More data from phase 3 trials are needed to validate the use of GLP-1 agonists as a therapeutic option for NASH, but initial data appear promising. 60 , 61 …”

Section: The Effect Of Weight Loss and Treatment Optionsmentioning

confidence: 99%

Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss

Popov

Lim

2015

JCTH

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) represents a rapidly growing cause of chronic liver disease in the United States and is associated with significant morbidity and mortality, including progression to liver cirrhosis and hepatocellular carcinoma. NAFLD comprises a spectrum of liver conditions, ranging from simple steatosis to steatosis with inflammation (steatohepatitis) and progressive fibrosis. Weight loss represents a first line therapeutic modality for the management of NAFLD. Herein, we review the evidence base for medical, surgical, and endoscopic approaches to weight loss and their potential impact on the natural history of NAFLD.

show abstract

“…More data from phase 3 trials are needed to validate the use of GLP-1 agonists as a therapeutic option for NASH, but initial data appear promising. 60 , 61 …”

Section: The Effect Of Weight Loss and Treatment Optionsmentioning

confidence: 99%

Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss

Popov

Lim

2015

JCTH

View full text Add to dashboard Cite

show abstract

“…The intense pharmacologic research on NASH might narrow the gap. 15 Finally, preliminary data in abdominally obese subjects treated with GFT505 are very promising. 12 Several compounds are being tested; as with the pharmacologic treatment of obesity, 13 subjects combining lifestyle intervention with drugs are likely to achieve greater and more sustainable weight loss, which might translate into NASH resolution.…”

Section: Weight Loss For a Healthy Livermentioning

confidence: 99%

Weight Loss for a Healthy Liver

2015

View full text Add to dashboard Cite

“…124 At the 2015 International Liver Congress in Vienna, Dr. Phillip Newsome's group presented the final results of their LEAN trial (Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis), which consisted of 52 patients with biopsyproven NASH. 125 Participants were randomized to receive either 1.8 mg/d of liraglutide subcutaneously or placebo. The primary endpoint of this trial, resolution of NASH with no worsening of fibrosis, was observed in 39% of patients receiving liraglutide as compared with 9% in the placebo group (p ¼ 0.019).…”

Section: Exenatide and Liraglutidementioning

confidence: 99%

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Gawrieh

Chalasani

2015

Semin Liver Dis

View full text Add to dashboard Cite

Life style modifications and optimization of the management of cardio-metabolic comorbidities are currently the mainstay of treatment for patients with non-alcoholic fatty liver disease (NAFLD). Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end stage liver disease is specifically offered to patients with non-alcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, we will discuss state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a select group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin or ursodeoxycholic acid. We also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor (FXR) ligand, obeticholic acid.

show abstract

OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial

Cited by 5 publications

References 0 publications

Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss

Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss

Weight Loss for a Healthy Liver

Pharmacotherapy for Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About